Clinical trials: Depressive Disorder, Major
Major Depression, Treatment
fMRI Study of Treatment Changes in Major Depression
The overall purposes of this research are to determine if Cognitive Behavioral Therapy (CBT) has the same healing effect on the brain for people with depression as traditional antidepressants do, and in comparison to healthy…
- Trial name
- NCT01027559
- Testing
- Sertraline, Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Depression, Bipolar Disorder
Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder
The primary outcome of this study is to determine if predictors of response can select a population of patients with MDD that is effectively treatable by augmentation with ziprasidone.
- Trial name
- NCT01168674
- Testing
- ziprasidone, Sugar pill
- Volunteers
- 49 people
- Sponsor
- Tufts Medical Center
Major Depressive Disorder
Mini Theta Burst TMS in MDD Patients
This is not a treatment study. In this study, the researchers are primarily interested in examining whether functional MRI (fMRI)-guided transcranial magnetic stimulation (TMS) may be more effective than traditional TMS methods…
- Trial name
- NARSAD (NCT04014959)
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pennsylvania
Depression
Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder
To evaluate the effectiveness of one algorithm for Major Depression Disorder (MDD) using medications available in the Brazilian Public Healthcare System (SUS), and assessment of the quality of life of these patients.
- Trial name
- NCT02901249
- Testing
- sertraline, Nortriptyline, Lithium
- Volunteers
- 68 people
- Sponsor
- Federal University of Rio Grande do Sul
Major Depressive Disorder
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
This is a phase 3, flexible-dose, open-label, multi-center study. The subjects who complete the week 8 visit in the prior double-blind study (B2411263) will be eligible to participate in this study.
- Trial name
- NCT01485887
- Testing
- Venlafaxine ER
- Where
- 25 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Mild Cognitive Impairment (MCI), Depression
Brain Aging and Treatment Response in Geriatric Depression
The proposed project will evaluate the role of neuroimaging biomarkers of brain aging (i.e., neurodegenerative and vascular brain changes) and mild cognitive impairment in the patterns of treatment response to memantine combined…
- Trial name
- NCT01902004
- Testing
- Escitalopram, Memantine
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- University of California, Los Angeles
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression
This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression.
- Trial name
- NCT06558344
- Testing
- 5 mg BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912
- Where
- 41 sites in United States, Japan
- Volunteers
- 225 people
- Sponsor
- Boehringer Ingelheim
Depression
Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression
This study will determine the effectiveness of motivational interviewing in improving antidepressant medication adherence among Hispanics.
- Trial name
- NCT00356304
- Testing
- Motivational interviewing, Treatment as usual
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Major Depressive Disorder
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
The purpose of this study is to assess the safety and effect of TC-5214 as a single therapy in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01288079
- Testing
- TC-5214, Duloxetine
- Where
- 63 sites in United States, Estonia and 3 more
- Volunteers
- 145 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
The clinical trial will investigate the effect of brexpiprazole on the concept of life engagement in participants with Major Depressive Disorder (MDD) with a current depressive episode.
- Trial name
- NCT04830215
- Testing
- Brexpiprazole
- Where
- Canada
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Study to Evaluate Treatment Effects Associated With the NeuroStar SoftStart Treatment Feature
The purpose of this study is to evaluate the comfort of the NeuroStar® Advanced Therapy System regular prescribed TMS protocol versus a New Feature.
- Trial name
- Comfort Start (NCT05535062)
- Testing
- repetitive Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Neuronetics
Depression, Depressive Disorder, Major
A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise
This pilot study aims to test a model that predicts that enhanced neurotransmitter gamma-aminobutyric acid (GABA) function in reward and affect-regulation central nervous system (CNS) circuits mediates the antidepressant effects…
- Conditions
- Depression, Depressive Disorder, Major, Depressive Disorder, Unipolar Depression
- Trial name
- MEDEX (NCT02407704)
- Testing
- Venlafaxine XR, Aerobic Exercise, Lorazepam
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Kirk Erickson, PhD
Depressive Disorder, Major
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder…
- Trial name
- Aspire II (NCT03097133)
- Testing
- Esketamine, Standard of Care
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 230 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Biological Markers of Response to Treatment in Major Depressive Disorder
The purpose of this study is to find out if two tests are useful in predicting whether someone with depression will get better when he or she is treated with an FDA approved antidepressant medication (either citalopram or…
- Trial name
- NCT00361218
- Testing
- open-label selective serotonin reuptake inhibitor (SSRI)
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major
An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of sirukumab as adjunctive treatment to antidepressant therapy (monoaminergic antidepressant) where sirukumab (administered as a 50 milligram (mg) subcutaneous (SC) injection…
- Trial name
- NCT02473289
- Testing
- Sirukumab 50 mg
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 193 people
- Sponsor
- Janssen Research & Development, LLC